Associated Papers
Chronic Myeloid Leukemia and the T315I BCR::ABL1 Mutation.
Pierro F et al.
International Journal of Molecular Sciences, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Comprehensive resistance profiling of chronic myeloid leukaemia associated ABL1 variants against five tyrosine kinase inhibitors using prime editing.
Jung Y et al.
Nature Biomedical Engineering, 2025
Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
Lan Y et al.
British Journal of Cancer, 2025
Somatic mutations and outcomes in chronic myeloid leukemia adolescent and young adults compared to children, adults, and BCR::ABL1-positive acute lymphoblastic leukemia.
Krizkova J et al.
Leukemia, 2025
Rare Atypical Ela3 BCR-ABL transcript in acute Lymphoblastic Leukemia: a case report.
Xu L et al.
African Health Sciences, 2025
Comprehensive analysis of tyrosine kinase domain mutations and imatinib resistance in chronic myeloid leukemia patients.
Dhangar S et al.
Leukemia Research, 2025
Advancing chronic myeloid leukemia research with next-generation sequencing: potential benefits, limitations, and future clinical integration.
Sutanto H et al.
Human Genetics, 2025
Timing and trajectory of BCR::ABL1-driven chronic myeloid leukaemia.
Kamizela AE et al.
Nature, 2025
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Innes AJ et al.
Leukemia, 2024
New ABL1 Kinase Domain Mutations in BCR::ABL1-Positive Acute Lymphoblastic Leukemia.
Li Z et al.
Cancer Medicine, 2024
A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience.
Datta G et al.
Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion, 2024
Validation of a novel NGS based BCR::ABL1 kinase domain mutation detection assay in Indian cohort.
Chaudhary P et al.
Scientific Reports, 2024
Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease.
Winter PS et al.
Biorxiv : the Preprint Server for Biology, 2024
Prediction of Conformational Ensembles and Structural Effects of State-Switching Allosteric Mutants in the Protein Kinases Using Comparative Analysis of AlphaFold2 Adaptations with Sequence Masking and Shallow Subsampling.
Raisinghani N et al.
Biorxiv : the Preprint Server for Biology, 2024
Concomitant L248V With E225V Mutation in the BCR-ABL Gene Associated With Rapid Chronic Myeloid Leukemia Lymphoid Blast Crisis.
Tungjitviboonkun S et al.
Cureus, 2024
A Retrospective Analysis of BCR-ABL1 Kinase Domain Mutations in the Frontline Drug Intolerant or Resistant Chronic Myeloid Leukemia Patients: An Indian Experience from a High-End Referral Laboratory.
Majumdar A et al.
South Asian Journal of Cancer, 2024
Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias.
Sponseiler I et al.
American Journal of Hematology, 2024
BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India.
S A et al.
Leukemia Research Reports, 2024
BCR::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C et al.
European Journal of Haematology, 2023
Mining cancer genomes for change-of-metabolic-function mutations.
Tu KJ et al.
Communications Biology, 2023
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Shanmuganathan N et al.
Haematologica, 2023
Droplet digital polymerase chain reaction improves the detection of BCR-ABL1 kinase domain mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Wan L et al.
International Journal of Laboratory Hematology, 2023
Chronic myeloid leukemia kinase domain mutations: A retrospective descriptive study on the therapeutic and prognostic significance in patients at King Edward VIII Hospital, KwaZulu-Natal, South Africa.
Benjamin C et al.
Health Science Reports, 2023
Molecular BCR::ABL1 Quantification and ABL1 Mutation Detection as Essential Tools for the Clinical Management of Chronic Myeloid Leukemia Patients: Results from a Brazilian Single-Center Study.
Marin AM et al.
International Journal of Molecular Sciences, 2023
A customized mass array panel for BCR::ABL1 tyrosine kinase domain mutation screening in chronic myeloid leukemia.
Limsuwanachot N et al.
Journal of Mass Spectrometry and Advances in the Clinical Lab, 2023
Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia.
Hasanova A et al.
Pathology Oncology Research : Por, 2023
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia.
Soverini S et al.
Leukemia, 2022
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA.
Sánchez R et al.
Scientific Reports, 2022
P-Loop mutations-Negative prognosticators in tyrosine kinase inhibitors resistant chronic myeloid leukemia patients.
Kaleem B et al.
International Journal of Laboratory Hematology, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D et al.
Critical Reviews in Oncology/hematology, 2022
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation.
Shetty D et al.
Asia-pacific Journal of Clinical Oncology, 2022
Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening.
Schaal W et al.
Cancer Informatics, 2022
Nanopanel2 calls phased low-frequency variants in Nanopore panel sequencing data.
Popitsch N et al.
Bioinformatics (oxford, England), 2021
The role of E255K/V-inclusive mutations in a Philadelphia-positive acute lymphoblastic leukemia with mutation evolution during sequential TKIs therapies: A case report.
Zhao M et al.
Medicine, 2021
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S et al.
Leukemia, 2021
Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition.
Nussinov R et al.
Molecular Cancer Research : Mcr, 2021
Next-generation sequencing improves BCR-ABL1 mutation detection in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Soverini S et al.
British Journal of Haematology, 2021
A Review of Molecular and Genetic Diagnostics of Myeloid Malignancies with Emphasis on Diagnostics in Bosnia and Herzegovina.
Kurtovic-Kozaric A et al.
Acta Medica Academica, 2021
Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.
Carratt SA et al.
Biomarker Research, 2021
Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J et al.
Theranostics, 2021
Somatic Mutations in Oncogenes Are in Chronic Myeloid Leukemia Acquired De Novo via Deregulated Base-Excision Repair and Alternative Non-Homologous End Joining.
Curik N et al.
Frontiers in Oncology, 2021